Form 4: Director Regina Groves Receives Fulgent Genetics Equity

Director Regina E. Groves was granted 11,117 restricted stock units in Fulgent Genetics, Inc. as part of a standard equity compensation plan.

Summary

• Director Regina E. Groves acquired 11,117 restricted stock units (RSUs) of Fulgent Genetics, Inc. (FLGT) on May 14, 2026.
• The transaction was granted at a price of $0 per share, representing equity-based compensation.
• Following this transaction, the director's total beneficial ownership of common stock increased to 28,099 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a signal of operational performance.

Positives

• The grant aligns the director's long-term interests with those of shareholders through a four-year vesting schedule.
• The increase in beneficial ownership demonstrates a commitment to the company's long-term performance.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Vesting is subject to continued service, creating a dependency on the director's ongoing tenure with the company.

Future Outlook

The RSUs vest over a four-year period, with 25% vesting after 12 months and the remainder vesting quarterly over the following 36 months, contingent on continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology and diagnostics sector to ensure board alignment with shareholder value creation.

Comparison to Industry Standards

• The four-year vesting schedule is consistent with standard equity compensation practices for board members in the U.S. healthcare and diagnostics industry.
• The grant size is typical for mid-cap biotechnology firms of similar market capitalization to Fulgent Genetics.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.
• The board maintains alignment with long-term company objectives through equity-based incentives.

Next Steps

• The director will continue to serve on the board, with the first portion of the granted RSUs scheduled to vest on May 14, 2027.

Key Dates

Keywords

Fulgent Genetics, FLGT, Form 4, Insider Trading, Equity Compensation, Director Ownership